SOURCE: USDM Life Sciences

USDM Life Sciences

March 04, 2014 10:35 ET

USDM Life Sciences to Discuss UDI Final Rule and Compliance at Medical Device Manufacturers Association FDA Forum

SANTA BARBARA, CA--(Marketwired - Mar 4, 2014) -  USDM Life Sciences, a leading global regulatory consulting firm in the life sciences industry, is pleased to announce Jay Crowley, Vice President of the Unique Device Identification Practice at USDM Life Sciences, will discuss UDI regulations at the Medical Device Manufacturers Association FDA Forum. Crowley will also discuss USDM's UDI solutions and services.

"I'm looking forward to discussing how medical device companies should achieve UDI compliance and help them utilize the benefits of UDI," said Crowley. "USDM is uniquely positioned to help medical device companies become UDI compliant because of our well-established relationships with the most successful IT vendors in the world."

As Vice President of the UDI Practice at USDM Life Sciences, Crowley helps medical device manufacturers achieve regulatory compliance, internal benefits and competitive advantage with UDI implementation.

Crowley spent nearly 27 years working at FDA. Most recently, he was Senior Advisor for Patient Safety, in FDA's Center for Devices and Radiological Health. Crowley had primary responsibility for the development and implementation of FDA's Unique Device Identification System. 

Crowley will speak at the Implementing UDI session at 11:00 am on Thursday, March 6th. The MDMA FDA Forum is March 5-6 at the Crowne Plaza Cabana Hotel in Palo Alto, CA.

About USDM Life Sciences:
USDM Life Sciences is a leading global regulatory consulting firm providing compliance, validation, qualification, quality, auditing and information technology services via project teams and staff augmentation to our clients in the medical device, biotechnology, biologics, diagnostics and pharmaceutical industries. USDM Life Sciences has more than 14 years of experience supplying our clients in the life science industry with compliance services during each phase of their drug and product development cycle while partnering with best of breed organizations to help companies simplify, unify and optimize their business and compliance objectives. For more information, please visit

Contact Information